Report on transactions of executives and related parties in Coloplast shares and related securities
According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.
The below transactions concern allocation of share options.
For further details, reference is made to Coloplast’s Remuneration Policy which was adopted in 2021. The policy is available on the group website at this address:
https://investor.coloplast.com/investor-relations/governance/policies_and_positions/
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Kristian Villumsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | President & CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | ||
| a) | Name | Coloplast A/S (CVR-no.: 69749917) | |
| b) | LEI | 529900NN7SOJ5QG82X67 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Share options relating to B shares | |
| Identification code | ISIN: DK0060448595 (B shares) | ||
| b) | Nature of the transaction | Share option allocation | |
| c) | Price and volume | Price | Volume |
| 0.00 | 45,036 | ||
| d) | Aggregated information | ||
| – Aggregated volume | 45,036 share options | ||
| – Price | DKK 0.00 | ||
| e) | Date of the transaction | 2023-02-03, 13:23 UTC | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Anders Lonning-Skovgaard | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President & CFO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | ||
| a) | Name | Coloplast A/S (CVR-no.: 69749917) | |
| b) | LEI | 529900NN7SOJ5QG82X67 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Share options relating to B shares | |
| Identification code | ISIN: DK0060448595 (B shares) | ||
| b) | Nature of the transaction | Share option allocation | |
| c) | Price and volume | Price | Volume |
| 0.00 | 22,925 | ||
| d) | Aggregated information | ||
| – Aggregated volume | 22,925 share options | ||
| – Price | DKK 0.00 | ||
| e) | Date of the transaction | 2023-02-03, 13:23 UTC | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Paul Marcun | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Growth | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | ||
| a) | Name | Coloplast A/S (CVR-no.: 69749917) | |
| b) | LEI | 529900NN7SOJ5QG82X67 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Share options relating to B shares | |
| Identification code | ISIN: DK0060448595 (B shares) | ||
| b) | Nature of the transaction | Share option allocation | |
| c) | Price and volume | Price | Volume |
| 0.00 | 22,822 | ||
| d) | Aggregated information | ||
| – Aggregated volume | 22,822 share options | ||
| – Price | DKK 0.00 | ||
| e) | Date of the transaction | 2023-02-03, 13:23 UTC | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Allan Rasmussen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Global Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | ||
| a) | Name | Coloplast A/S (CVR-no.: 69749917) | |
| b) | LEI | 529900NN7SOJ5QG82X67 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Share options relating to B shares | |
| Identification code | ISIN: DK0060448595 (B shares) | ||
| b) | Nature of the transaction | Share option allocation | |
| c) | Price and volume | Price | Volume |
| 0.00 | 19,999 | ||
| d) | Aggregated information | ||
| – Aggregated volume | 19,999 share options | ||
| – Price | DKK 0.00 | ||
| e) | Date of the transaction | 2023-02-03, 13:23 UTC | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Nicolai Buhl Andersen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Innovation | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | ||
| a) | Name | Coloplast A/S (CVR-no.: 69749917) | |
| b) | LEI | 529900NN7SOJ5QG82X67 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Share options relating to B shares | |
| Identification code | ISIN: DK0060448595 (B shares) | ||
| b) | Nature of the transaction | Share option allocation | |
| c) | Price and volume | Price | Volume |
| 0.00 | 18,888 | ||
| d) | Aggregated information | ||
| – Aggregated volume | 18,888 share options | ||
| – Price | DKK 0.00 | ||
| e) | Date of the transaction | 2023-02-03, 13:23 UTC | |
| f) | Place of the transaction | Outside a trading venue | |
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Kristine Husted Munk
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com
Press and media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR)
no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ more than 14,500 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2023-02.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachment
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…